[HTML][HTML] From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options
A Gastaldelli, K Cusi - JHEP reports, 2019 - Elsevier
The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have
reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect …
reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect …
DPP4 in diabetes
D Röhrborn, N Wronkowitz, J Eckel - Frontiers in immunology, 2015 - frontiersin.org
Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …
Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial
TR Joy, CA McKenzie, RG Tirona… - World journal of …, 2017 - pmc.ncbi.nlm.nih.gov
AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic
parameters of non-alcoholic steatohepatitis (NASH). METHODS Twelve patients with biopsy …
parameters of non-alcoholic steatohepatitis (NASH). METHODS Twelve patients with biopsy …
[PDF][PDF] Сахарный диабет 2 типа
АС Аметов - Проблемы и решения. Москва: ГЭОТАР-Медиа, 2014 - e-library.sammu.uz
Аннотация Современная диабетология обращает самое серьезное внимание на
метаболизм жировой ткани потому, что жировая ткань очень тесно связана с …
метаболизм жировой ткани потому, что жировая ткань очень тесно связана с …
Fructose beverage consumption induces a metabolic syndrome phenotype in the rat: a systematic review and meta-analysis
A high intake of refined carbohydrates, particularly the monosaccharide fructose, has been
attributed to the growing epidemics of obesity and type-2 diabetes. Animal studies have …
attributed to the growing epidemics of obesity and type-2 diabetes. Animal studies have …
[PDF][PDF] Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis
Abstract Background & Aims: Preliminary evidence suggests that inhibi-tion of dipeptidyl
peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes …
peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes …
Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats
Background Since many diabetic patients require combination therapy, the use of herbal
remedies with anti-diabetic activity represents a vital option in diabetes mellitus (DM) …
remedies with anti-diabetic activity represents a vital option in diabetes mellitus (DM) …
Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats
K Kaji, H Yoshiji, Y Ikenaka, R Noguchi… - Journal of …, 2014 - Springer
Background Dipeptidyl peptidase-4 inhibitor (DPP4-I) is clinically used as a new oral
antidiabetic agent. Although DPP4 is reportedly associated with the progression of chronic …
antidiabetic agent. Although DPP4 is reportedly associated with the progression of chronic …
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity
M Kern, N Klöting, HG Niessen, L Thomas, D Stiller… - Plos one, 2012 - journals.plos.org
Linagliptin (tradjenta™) is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4
inhibition attenuates insulin resistance and improves peripheral glucose utilization in …
inhibition attenuates insulin resistance and improves peripheral glucose utilization in …
Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial
Background/purpose Dipeptidyl peptidase 4 (DPP-4) expression is directly associated with
hepatic lipogenesis and liver injury in nonalcoholic steatohepatitis (NASH). This study has …
hepatic lipogenesis and liver injury in nonalcoholic steatohepatitis (NASH). This study has …